Levetiracetam Effective as Episodic Migraine Prophylactic
Insufficient evidence is available to determine the efficacy of levetiracetam as a chronic migraine prophylactic.
Poor sleep quality is prevalent among patients with probable migraine and is associated with an exacerbation of probable migraine symptoms.
The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period.
Galcanezumab treatment may result in functional improvements and a reduction in the impact of headaches on quality of life in patients with migraine.